Oxygen is a necessary medication for the treatment of lung diseases. To adequately address the extraordinary rise in demand on our healthcare systems produced by the COVID-19 epidemic, imaginative changes are required. According to Chinese data, 40% of responders COVID-19 experience symptoms, 15% have severe symptoms requiring oxygen therapy, and 5% will be very sick requiring intensive care unit treatment. Home treatment and monitoring of asymptomatic or moderately unwell sufferers can be easily adapted to reduce the load on the healthcare system while preserving the safety and efficacy of therapy. According to the necessity of oxygen, we have contributed a medical device that filtration ambient air via molecular sieve beds to concentrate room oxygen using PSA (pressure swing adsorption) technology, which separates nitrogen from oxygen in the ambient air to therapeutic levels for patient administration. The supply of concentrated oxygen to the patient to improve and stabilize glycated hemoglobin levels is known as oxygen therapy for the treatment of hypoxemia. In developing-country contexts, this device is a suitable and preferable choice for providing point-of-care oxygen, particularly if cylinders and piped systems are ineffective or unavailable.